CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Sienna Biopharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Sienna Biopharmaceuticals Inc
30699 Russell Ranch Rd Ste 140
Phone: (818) 629-2256p:818 629-2256 WESTLAKE VILLAGE, CA  91362-7327  United States Ticker: SNNAQSNNAQ

Filed for Bankruptcy on 9/16/2019
This company ceased filing statements with the SEC on 12/11/2019.
Case #19-12051, filed in the U.S. Bankruptcy Court for the District of Delaware
On 12/18/2019, the voluntary petition for the Company for reorganization under Chapter 11 was converted to Chapter 7.

Business Summary
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on bringing scientific innovations to patients whose lives remain burdened by their disease. Its lead candidate from its platform, SNA-120, is an inhibitor of Tropomyosin receptor kinase A (TrkA) for the treatment of psoriasis, as well as the associated pruritus (itch). The Company's second product candidate, SNA-125, is a dual Janus kinase 3 (JAK3)/TrkA inhibitor for the treatment of atopic dermatitis, psoriasis and the associated pruritus. In addition, the Company also offers SNA-001, a silver photo particle technology derived from its Topical Photoparticle Therapy platform.
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201912/31/2018YesYesYes-Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief Executive Officer and Director Frederick C.Beddingfield III
Chairman of the Board Keith R.Leonard 62 1/1/2016 1/1/2016
Chief Financial Officer RichardPeterson
16 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sienna Biopharmaceuticals S.r.l Via Ribes, 5 Colleretto Giacosa Ivrea Italy

Business Names
Business Name
Creabilis Holdings Limited
Creabilis UK Limited
Sienna Biopharmaceuticals S.A.
5 additional Business Names available in full report.

General Information
Number of Employees: 13 (As of 11/11/2019)
Outstanding Shares: 30,907,542 (As of 11/7/2019)
Shareholders: 91
Stock Exchange: OTC
Federal Tax Id: 273364627
Fax Number: (302) 655-5049


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, July 17, 2024